Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia is a research paper published in Cancer Discovery (2020). On theSindex it has a DataRank of 3.1. It has been cited 79 times, with 66 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.657
From this paper's citation signal
Citation Network Contribution
2.4
From 60 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 66 citers.
NIH
Grant: P30 CA016058
NIH
Grant: R01 CA197870
NIH
Grant: R35 CA198183
NCI NIH HHS
Grant: R35 CA197734
National Institutes of Health
Grant: 5R01CA197870-03
Improving BTK Directed Therapy for CLL
National Institutes of Health
Grant: 3P30CA016058-15S1
CORE--HORMONE RECEPTOR LABORATORY
Leukemia and Lymphoma Society
Ohio State University
FWCI
7.41
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals